Company intelligence / Profile preview
Almirall
Barcelona, Catalonia, Spainalmirall.com ↗
- Ownership
- Public · ALM
- Employees
- ~2027
- Development stage
- Commercial
01
Overview
Almirall has a robust commercial portfolio in medical dermatology with several late-stage and marketed products for psoriasis (Ilumetri/tildrakizumab), atopic dermatitis (Ebglyss/lebrikizumab), actinic keratosis (Klisyri/tirbanibulin), acne (Seysara/sarecycline) and more. Recent clinical progress includes regulatory approvals for efinaconazole in Europe and label expansions for existing products. The company’s early pipeline features novel mAbs targeting autoimmune skin diseases with multiple proof-of-concept studies planned or underway.
- Therapeutic areas
- DermatologyInfectious DiseasesRheumatology
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)fusion proteins
- Industry
- Biotech
02
Drug pipeline
42 assets41 more assets in the full pipeline.
Request access →03
Partnerships
Sun Pharma (tildrakizumab development)Eli Lilly & Co. (lebrikizumab development)Simcere Pharmaceutical Groupother collaborations with small/mid-size biotechs and academic partners
04
Financials
- Market cap
- $5.4B
- Total revenue
- $30.3M
- Enterprise value
- $5.1B
Beyond the preview
Go deeper on Almirall.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Almirall.